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BACKGROUND: Novel technologies to redirect T-cell killing against cancer cells are emerging. We hypothesised that metastatic human
colorectal cancer (CRC) previously treated with conventional chemotherapy would be sensitive to T-cell killing mediated by
carcinoembryonic antigen (CEA)/CD3-bispecific T-cell-engaging BiTE antibody (MEDI-565).
METHODS: We analysed proliferation and lysis of CEA-positive (CEAþ) CRC specimens that had survived previous systemic
chemotherapy and biologic therapy to determine whether they could be killed by patient T cells engaged by MEDI-565 in vitro.
RESULTS: At low concentrations (0.1–1ngml
 1), MEDI-565þ T cells caused reduced proliferation and enhanced apoptosis of CEAþ
human CRC specimens. High levels of soluble CEA did not impair killing by redirected T cells and there was no increase in resistance
to T-cell killing despite multiple rounds of exposure.
CONCLUSIONS: This study shows for the first time that metastatic CRC specimens derived from patients previously treated with
conventional chemotherapy can be lysed by patient T cells. Clinical testing of cancer immunotherapies, such as MEDI-565 that result
in exposure of tumours to large numbers of T cells, is warranted.
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Antigen-specific cytotoxic T cells (CTLs) have the capacity to kill
human cancers, as showed by tumour regression after adoptive
transfer of ex vivo-expanded tumour-infiltrating lymphocytes
(TILs) and T-cell receptor gene-transfected T cells to melanoma
patients (Leen et al, 2007). However, generating antigen-specific
T cells in vitro for adoptive transfer is complicated, time-
consuming and at best, is only successful in 70% of TIL cultures
(Dudley et al, 2003). An alternative is to redirect large numbers
of T cells through the use of bispecific antibodies, which
target CD3 on T cells and a surface antigen on tumour cells,
including bispecific single-chain antibodies of the BiTE class
(Wolf et al, 2005). These recombinant constructs transiently link
resting T cells to tumour cells, leading to T-cell activation and
serial lysis of tumour cells (Hoffmann et al, 2005; Brandl et al,
2007; Brischwein et al, 2007). Mouse models have shown high
levels of activity of BiTE antibodies targeted against EphA2
and CD19 (Dreier et al, 2003; Schlereth et al, 2006; Brischwein
et al, 2006; Offner et al, 2006; Hammond et al, 2007). Witthauer
et al (2008) reported that a BiTE targeting EpCAM could lead to
T-cell-mediated killing of breast cancer cells in pleural effusions.
Recently, Bargou et al (2008) reported clinical activity and a
safety profile suitable for continued development of the BiTE
antibody blinatumomab (also called MT103/MEDI-538) with dual
specificity for CD19 and CD3 in a study of non-Hodgkin’s B-cell
lymphoma patients who had experienced relapse after standard
therapies.
MEDI-565, also known as MT111, is composed of a human
single-chain antibody recognising carcinoembryonic antigen
(CEA, CD66e and CEACAM5), which is frequently expressed in
carcinomas of the lung, pancreas, stomach, ovary, uterus, breast,
colon and rectum (Hammarstrom, 1999), and a de-immunised
single-chain antibody specific for CD3, which is connected by a
short flexible linker sequence (Lutterbuese et al, 2009). Conven-
tional CEA-specific antibodies can bind with high affinity and
selectivity to CEA-expressing (CEAþ) tumours in vivo but they do
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snot recognise CEA expressed on the luminal side of several normal
epithelial tissues, thus limiting their potential toxicity
(Mayer et al, 2000). The bispecific BiTE antibodies, CEA/CD3,
were recently shown to prevent subcutaneous tumour growth and
formation of lung metastases in preclinical models (Lutterbuese
et al, 2009).
The purpose of our study was to determine whether T cells from
normal donors or cancer patients could be redirected by MEDI-565
to kill human colorectal cancer specimens that had survived
previous chemotherapy treatment. We aimed to confirm the
function of MEDI-565 with the T cell of cancer patients and against
human colorectal cancers. Furthermore, we aimed to confirm that
the mechanism of killing by MEDI-565 was similar to that of other
forms of T-cell-mediated killing. Finally, we wanted to determine
whether tumours remained sensitive to repeated rounds of
exposure to MEDI-565. We found that tumour cells, from patients
previously treated with chemotherapy, had their growth inhibited
and underwent apoptotic cell death when exposed to combinations
of T cells with MEDI-565.
MATERIALS AND METHODS
Reagents
Fluorescein isothiocyanate-anti-lineage cocktail 1mAb, PerCP-
anti-CD4mAb, APC-anti-CD8mAb, PE-anti-CD69mAb, PE-anti-
CD25mAb, FITC-anti-granzyme B mAb, PE-anti-Fas ligand mAb
and streptavidin-APC were purchased from BD Biosciences
(San Jose, CA, USA). Fluorescein isothiocyanate-labelled and
PE-labelled anti-CEA mAbs were from Sanquin (Amsterdam,
The Netherlands), and 7-AAD and Annexin V-biotin kit were
purchased from Immunotech (Marseille, France, cat no. PN
IM3422). Ethylene glycol tetraacetic acid (EGTA) was obtained
from Sigma (St Louis, MO, USA), and purified human CEA protein
was purchased from TriChem (West Chester, PA, USA).
Construction and production of bispecific antibodies
Standard DNA technologies were used to construct MEDI-565, also
known as MT111, and the control MEC14 BiTE, as described
(Lutterbuese et al, 2009). The selection of MEDI-565 was from a set
of bispecific single-chain antibodies (Lutterbuese et al, 2009) and
possessed a set of characteristics identified as important for
development of a biological drug. It is composed of a humanised
anti-CEA single-chain antibody (Chester et al, 1994) and a
‘de-immunised’ human CD3e-specific single-chain antibody
derived from the mouse monoclonal antibody L2K (Brischwein
et al, 2006). MEC14 BiTE is composed of a murine anti-Mecoprop
(an herbicide) single-chain antibody linked to the same anti-CD3e
single-chain antibody used to construct MEDI-565. The expression
vector pEF-DHFR containing the coding sequences of MEDI-565
or MEC14 BiTE (Cont BiTE) was transfected into DHFR-deficient
CHO cells. Each antibody was purified from CHO cell culture
supernatants using immunobilised metal affinity chromatography
and gel filtration essentially as described (Kufer et al, 2001).
Antibody preparations containing primarily the monomeric form
(497%) of each bispecific antibody was used in all experiments.
Tumour cell lines
Ls174T (ATCC CCL-188), a CEA highly expressing colon
carcinoma cell line, AsPC-1 (ATCC CRL-1682), a CEAþ
pancreatic adenocarcinoma cell line and SW480 (ATCC CCL-
228) and HCT116 (ATCC CCL-247), the CEA-negative colorectal
carcinoma cell lines, were purchased from ATCC (Manassas, VA,
USA). The cell lines were cultured in RPMI1640 medium
supplemented with 10% fetal bovine serum (Invitrogen Life
Technologies, Carlsbad, CA, USA).
Mice
NOD.CB17-Prkdcscid/J (NOD/SCID) mice were purchased from
Jackson Laboratory (Bar Harbor, ME, USA) and bred in the Duke
Comprehensive Cancer Center Isolation Facility. All work was
performed in accordance with the approved protocol of the Duke
IACUC.
Tumour cell isolation from patients’ colorectal cancer
specimens and establishment of explants in NOD/SCID
mice
Patients undergoing resection of colorectal cancer metastatic to the
liver, which were refractory to standard chemotherapy (including
fluorouracil, oxaliplatin and bevacizumab), provided signed
informed consent approved by the Duke University Medical
Center Institutional Review Board before surgery. After the
collection of the colorectal cancer specimen, the tissue was minced
with a blade into pieces smaller than 2mm cube and digested
overnight with triple enzyme buffer containing collagenase IV
(1mgml
 1, Sigma, no. C-5138), hyaluronidase (100mgml
 1,
Sigma, no. H-6254) and deoxyribonuclease (20Uml
 1, Sigma,
no. D-5025) in RPMI1640 medium. The cells were spun down,
washed with PBS thrice, resuspended in Hank’s balanced salt
solution and mixed with Matrigel (BD Biosciences) in a 1:1 ratio.
Cells (half of available cells from digestion procedure, typically
1 10
6 cells) were injected into the back of NOD/SCID mice. After
2- to 4-month growth in vivo, when tumours reached approxi-
mately 1cm in diameter, the mice were killed and the tumours
were excised, minced and put into in vitro culture. Some of the
minced cells were injected into the flank of NOD/SCID mice, and
serial in vivo passages were performed. Colorectal cancer (CRC)
cells growing in vitro were used as target cells of the assays. These
cells (CRC007, CRC010 and CRC039) were analysed for their HLA
class I expression and CEA expression, and were proven to be
positive for both molecules.
Flow-based cytotoxicity assay
T cells were negatively isolated from the PBMCs of the normal
donors or patients using a T-cell isolation kit (Invitrogen Dynal
AS, Oslo, Norway, cat no. 113.11D). In all experiments, purity of
CD3þ cells exceeded 95% of the CD45þ leukocyte population
after isolation procedures. For the cytotoxicity assays, 1 10
5
tumour cells and 5 10
5 negatively isolated T cells were put into
96-well U-bottom plates with MEDI-565 or Cont BiTE at
concentrations ranging from 0.01 to 10000ngml
 1. Alternatively,
in some experiments using 12-well plates, 5 10
5 tumour cells and
2.5 10
6 T cells were added to each well with MEDI-565 or Cont
BiTE. After 1–7 days of incubation, all cells were harvested with
0.05% trypsin/EDTA and spun down by centrifugation. Cells were
then stained with anti-CEA-FITC and 7-AAD or propidium iodide,
and CEAþ cells were analysed for their viability after acquisition
using a FACSCalibur flow cytometer (BD Biosciences). Alterna-
tively, cells were labelled with biotin-conjugated Annexin V, and
then stained with anti-CEA-PE, 7-AAD and Streptavidin-APC. The
CEAþ cells were analysed for expression of Annexin V as a
marker of apoptosis. To test whether cytotoxicity was dependent
on exocytosis of cytotoxic granules, the assay was performed in
the presence of 4mM EGTA, a chelator of extracellular
calcium required for exocytosis (Lowin et al, 1996; Voskoboinik
et al, 2005, 2006).
MTT assay
The tumour cells, AsPC-1, were cultured with T cells in a 1:5
ratio for 7 days in the presence of MEDI-565 or Cont BiTE
(100ngml
 1). On day 7, floating cells were discarded and only
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sadherent AsPC-1 cells were harvested with 0.05% trypsin/EDTA
and washed with PBS thrice. 1 10
4 AsPC-1 tumour cells were
added to each well of 96-well flat-bottom plates in 200mlo f
complete RPMI1640 medium. The cells were allowed to adhere
to the plates overnight at 371C (day 0) and were further incubated
for 1, 2, 4 or 7 days. A total of 20mlo f1 0  3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyl-tetrazolium bromide (MTT, 5mgml
 1) solution
was added to each well, and incubated at 371C for 2h. The
adherent cells were lysed with 150ml of dimethylsulphoxide
(DMSO) and the optical density (OD) at 550nm was measured.
Sensitivity of colorectal cancer cells to oxaliplatin was also deter-
mined using MTT assay. In brief, 1 10
4 CRC cells were added
to each well of 96-well flat-bottom plates and, after overnight
incubation, various concentrations of oxaliplatin were added to the
wells. The MTT assay was performed after 72-h incubation with
oxaliplatin and the IC50 was reported as the concentration at which
50% reduction in cell proliferation occurred.
Trypan blue dye exclusion assay
To assess MEDI-565 effects on tumour cell proliferation, tumour
cells (0.5 10
6 per well) were cultured with or without T cells
(2.5 10
6 per well) for 5 or 7 days in 12-well plates in the presence
of MEDI-565 or Cont BiTE (each at 100ngml
 1). Photographs
were taken at the magnifications of  40,  100 and  200, and
the numbers of tumour cell/T-cell clusters, tumour cell attached by
at least three lymphocytes, were counted in three random high-
power fields ( 100). Cells were harvested with 0.05% trypsin/
EDTA and Trypan blue dye was added after which the sum of
viable tumour cells (Trypan blue negative) and dead cells (Trypan
blue staining) was determined. Smaller cells (morphologically
T cells) were eliminated from counting.
Cell-cycle analysis
The tumour cells, AsPC-1, were cultured with normal donor’s
T cells in a 1:5 ratio for 7 days in the presence of MEDI-565 or
Cont BiTE (100ngml
 1). On day 7, floating cells were discarded
and only adherent AsPC-1 cells were harvested from flasks with
0.05% trypsin/EDTA, washed with PBS and resuspended in 0.5ml
of 0.1% glucose/PBS, and cells were then fixed by gently adding
5ml of cold 70% ethanol. Cells were kept at 41C overnight, and
then washed with PBS twice. Propidium iodide was added to the
cell suspension, and incubated at 371C for 30min. Cells were
acquired using FACSCalibur flow cytometer (BD Biosciences), and
DNA content was analysed for tumour cells. Tumour cells were
gated based on the size and granularity in forward scatter and side
scatter histogram.
Intracellular cytokine staining
2.5 10
6T cells and 5 10
5 AsPC-1 cells were incubated in the
presence of MEDI-565 or Cont BiTE (each at 100ngml
 1)f o r1 ,2o r
4 days as described above. For the last 5h of the incubation period,
Brefeldin A (1mgml
 1) was added to the medium. Then, EDTA
(final concentration, 2mM) was added to the medium to dissociate
cells and after 10min the cells were harvested, washed with PBS twice
and fixed with 1% formaldehyde in PBS. Cells were permeabilised
with permeabilising solution (BD Biosciences) for 20min, and
stained with anti-CD4-PerCP, anti-CD8-APC and FITC-labelled anti-
granzyme B or PE-labelled anti-Fas ligand. Forward Scatter
low Side
Scatter
low CD4þ and CD8þ T cells were analysed for their
granzyme B or Fas ligand expression (Supplementary Figures).
Enzyme-linked immunosorbent assay
2.5 10
6 T cells and 5 10
5 AsPC-1 cells were incubated in the
presence of MEDI-565 or Cont BiTE (each at 100ngml
 1) for 1, 3
or 5 days and supernatants were harvested and kept frozen at
 801C until used. Supernatants were analysed using ELISA for the
presence of granzyme B and perforin (Mabtech Inc., Cincinnati,
OH, USA) according to the manufacturer’s instructions. Colour
was developed with 3,30,5,50,tetramethylbenzidine (TMB) stabilised
substrate (Promega, Madison, WI, USA), stopped by adding 1N
H2SO4, and OD at 450nm was analysed using ELISA plate reader
(Bio-Rad, Model 680, Hercules, CA, USA; Supplementary data).
Th1/Th2 CBA analysis
Culture supernatants were collected after 5 days of T-cell/tumour
cell co-incubation with MEDI-565 or Cont BiTE (each at
100ngml
 1). The concentrations of IL-2, IL-4, IL-5, IL-10, TNF-a
and IFN-g were measured with a BD Cytometric Bead Array Th1/
Th2 cytokine kit (BD Biosciences), according to the manufacturer’s
instructions, and analysed on a FACSCalibur flow cytometer using
BD CBA software (BD Biosciences; Supplementary data).
Statistical analysis
The Student’s t-test was used to analyse differences in tumour cell
killing between MEDI-565 and control MEC14 BiTE-treated
tumours. Differences at Po0.05 were considered statistically
significant.
RESULTS
Human CEAþ tumour cells are recognised and undergo
apoptosis by normal human donor T cells redirected by
MEDI-565
To examine the cytolytic effects of MEDI-565, the CEAþ human
pancreatic cancer cell line AsPC-1 was incubated with purified,
human T cells and MEDI-565 or a control BiTE (which binds the
herbicide mecoprop and human CD3; Cont BiTE) for 5 days. As
shown in Figure 1, in the presence of MEDI-565, but not Cont
BiTE, tumour cells were surrounded by T cells, detached from the
bottom of the wells, and showed apoptotic changes in cell
morphology. Similar observations were made when using human
CEAþ tumours (e.g., CRC039) obtained from resection specimens
as target cells. We found a markedly greater number of tumour
cells with adherent T cells in the MEDI-565 containing co-cultures
compared with the Cont BiTE containing cultures (AsPC-1:
23.0±3.6 vs 1.3±0.6 clusters per field, CRC039: 15.7±2.1 vs
1.7±1.5 clusters per field, Po0.005). These data show that MEDI-
565 redirects large numbers of T cells to engage tumour cells.
Proliferation of human CEAþ tumour cells is inhibited
and cytotoxicity is enhanced by T cells redirected by
MEDI-565
We analysed the cytotoxicity of tumour cells caused by MEDI-565
using flow cytometric analysis to detect uptake of a dye into killed
tumour cells. As shown in Figure 2A, the cytotoxicity of MEDI-565
required the presence of T cells, suggesting that MEDI-565 alone
does not cause cell death. We next analysed whether MEDI-565
reduced proliferation of tumour cells in the presence of T cells by
counting viable cells with Trypan blue dye exclusion. As shown in
Figure 2B, MEDI-565 significantly inhibited the cell proliferation
and resulted in only one-eighth of the number of viable tumour
cells in culture after a 7-day incubation period (Po0.05).
Interestingly, T cells proliferated in MEDI-565 containing
co-cultures, but not in Cont BiTE containing co-culture
(3.31±0.49 10
6 vs 0.72±0.11 10
6 cells per well), possibly
because of activation as evidenced by upregulation of CD69 and
CD25 observed only in MEDI-565 cultures. The expression
(percent positivity/mean fluorescence intensity (MFI)) of CD69
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sand CD25 by T cells in a representative MEDI-565 culture was
48.3%/301.5 and 20.3%/222.8, respectively, whereas it was 1.5%/
10.6 and 9.3%/36.4, respectively, in Cont BiTE cultures.
To evaluate the effect of MEDI-565 on the cell cycle of
tumour cells, we stained tumours with propidium iodide after
7 days of incubation in the presence of T cells with or without
MEDI-565 or Cont BiTE (Figure 2C). Only tumour cells cultured
with MEDI-565þ T cells had substantially smaller number
of cells in G2/M phase compared with all other conditions tested.
The proliferation of these cells for 7 days after treatment was
also monitored using MTT assay. As shown in Figure 2D, AsPC-1
tumour cells previously exposed to MEDI-565þ T cells prolifer-
ated significantly slower than tumour cells from other conditions,
suggesting an anti-proliferative effect of MEDI-565.
Normal donor- and cancer patient-derived T cells with
MEDI-565 induce comparable cytotoxicity against
CEAþ cancer cell lines in a CEA-specific manner
Our previous experiments used T cells from healthy human donors
as effector cells for the MEDI-565 antibody. In this study we tested
whether circulating T cells from colorectal cancer patients would
similarly function with MEDI-565 in lysing CEAþ cancer cells.
T cells from five normal donors and eight colorectal cancer patients
were used as effector cells and incubated with AsPC-1 cells in a 5:1
E:T ratio. Cells were incubated for 2 days, and the cytotoxicity was
analysed using flow cytometry with 7-AAD staining. As shown in
Figure 3A, T cells from cancer patients (right panel) caused
comparable cytotoxicity as T cells from healthy volunteer donors
(left panel) in the presence of the MEDI-565 antibody. There were no
statistically significant differences in induced cytotoxicities between
these two T-cell sources when compared at each MEDI-565
concentration (P¼0.73, 0.35, 0.45, 0.52, 0.83, 0.79 and 0.58 for 10
4,
10
3,1 0
2,1 0
1,1 0
0,1 0
 1 and 10
 2ngml
 1 BiTE concentration,
respectively, using Student’s t-test). These data suggest that cancer
patient T cells do not have an intrinsic deficit in their killing
potential when engaging tumours through MEDI-565.
To confirm that cytotoxicity was CEA specific, we tested
both CEAþ (Ls174T and AsPC-1) and CEA  (SW480 and
HCT116) cell lines in the presence of T cells and MEDI-565 or
Cont BiTE (Figure 3B). MEDI-565-induced T-cell cytotoxicity was
only observed with CEAþ cell lines, indicating surface antigen
specificity mediated by MEDI-565. In addition, cancer patient-
derived T cells showed comparable cytotoxicity against CEAþ
cancer cell lines, supporting the potential use of MEDI-565 in
patients with CEAþ cancers.
Normal donor- and cancer patient-derived T cells with
MEDI-565 induce apoptotic cell death of a CEAþ cancer
cell line
To examine the effect of MEDI-565 and T cells on apoptotic cell
death of tumour cells, AsPC-1 cells were incubated with T cells and a
range of MEDI-565 concentrations. On study days 1 to 4,
subpopulations of tumour cells undergoing apoptosis were identi-
fied by flow cytometry using annexin V and 7-AAD (Figure 3C).
Figure 3C shows the analysis at day 4 with predominantly early
apoptosis (annexin Vþ and 7-AAD ) with some component of late
apoptosis/cell death (annexin Vþ and 7-AADþ) over a wide range
of MEDI-565 concentrations (0.1–1000ngml
 1). Apoptosis was not
observed until day 2, but reached a maximum at day 4 (Figure 3D)
and did not consistently increase further by day 7 (data not shown).
CEAþ human metastatic colorectal tumour explants
are recognised and undergo reduced proliferation and
apoptotic cell death when exposed to T cells redirected
by MEDI-565
To provide a more clinically relevant assessment of MEDI-565
activity, we used the short-term cultured human metastatic
colorectal cancer cells derived from surgical resections of patients
previously treated with oxaliplatin and fluorouracil-containing
regimens. The colorectal cancer cells had been implanted into
NOD/SCID mice, grown, removed and then maintained in vitro.
Flow cytometric and immunohistochemical analyses showed that
these metastatic tumour explants expressed CEA, and had
histological characteristics of metastatic colorectal cancers (data
not shown). In addition, these explants (CRC007, CRC010 and
CRC039) were tested for their sensitivity to oxaliplatin in vitro and
were found to have IC50 of 2.5, 12.0 and 30.5mM, respectively.
Compared with the IC50 in a screen of colorectal cancer cell lines
treated with oxaliplatin (LS180, o0.3mM; Colo205, o0.3mM; and
HCT8, o0.3mM), these explants were determined to be relatively
insensitive to oxaliplatin. These metastatic tumour explants were
incubated with T cells isolated from healthy volunteer donors for 5
days (Figure 4 and Supplementary Figure 1). Metastatic tumour
explants cultured with MEDI-565, but not Cont BiTE, were
surrounded by T cells, detached from the bottom of the well,
and were gradually killed (Supplementary Figure 1). We confirmed
apoptotic cell death of cells from the metastatic tumour explants
incubated with MEDI-565 and T cells by annexin V and 7-AAD
staining using flow cytometry at day 5 (Figures 4A and B). The
average values of cytotoxicity of these three colorectal cancer
explants (CRC007, CRC010 and CRC039) from repeated assays are
shown in a bar graph (Figure 4B). MEDI-565 induced significantly
higher apoptotic cell death of CEAþ colorectal tumour explants
when compared with Cont BiTE or without BiTE antibody
condition (Po0.005). These data also indicate that, despite being
insensitive to oxaliplatin, human colorectal cancer cells are
sensitive to killing mediated by MEDI-565.
To assess the combined effects of reduced cell growth and
induction of apoptotic cell death, we also analysed the number of
live and dead cells using Trypan blue dye exclusion. Similar
reductions in total cells for all three cancer cell cultures were
observed (Figure 4C). Viable cancer cells in the presence of MEDI-
565 and T cells were reduced by 66–80% relative to Cont BiTE/T
cells, or no treatment. Thus, treatment of cultures with MEDI-565
MEDI-565
× 200
CRC039
AsPC-1
Cont-BiTE
Figure 1 MEDI-565 and T-cell (MEDI-565/T-cell)-mediated morpho-
logic changes of CEAþ cancer cells. Carcinoembryonic antigen-positive
human pancreatic cancer cell line, AsPC-1, and a CEAþ human colorectal
cancer explant (CRC039) were used as target cells. T cells, negatively
isolated from human PBMCs, were used as effector cells. 5 10
5 target
cells and 2.5 10
6 T cells were co-cultured in each well of 12-well plates
with 100ngml
 1 of MEDI-565 or MEC14 control BiTE (Cont BiTE). Cells
were incubated for 5 days at 371C, and photographed at  200
magnification.
T-cell-mediated killing of metastatic colon cancer cells
T Osada et al
127
British Journal of Cancer (2010) 102(1), 124–133 & 2010 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
scombined with T cells induced both anti-proliferative and/or
apoptotic effects on human metastatic tumour cells, resulting in a
massive reduction in the total number of viable tumour cells after
treatment compared with untreated tumour cells.
Granzyme B and FasL have a role in MEDI-565/T-cell-
induced apoptosis
It is known that T cells kill tumours by the perforin/granzyme B
and the Fas/FasL pathways. Therefore, we aimed to confirm that
these pathways were also potentially involved in MEDI-565-
induced apoptosis. Indeed, we observed greater percentages of
granzyme B-and FasL-expressing CD8þ T cells after co-culture of
tumours, T cells and MEDI-565 (Supplementary Figures 2 and 3)
when compared with control-BiTE. Interestingly, the MEDI-565
induced gradual secretion of perforin by T cells, which corres-
ponded to the slow induction of apoptosis in target cells. These
results indicate that the perforin/granzyme B system has an
important role in MEDI-565-induced T-cell cytotoxicity.
We next evaluated the cytokines secreted by T cells responding
to and destroying the CEAþ tumour cells in cultures containing
MEDI-565. Using beads to capture the cytokines, we showed
that IL-2, IL-4, IL-5, IL-10, TNF-a and IFN-g were all secreted, but
IFN-g was found in the highest amount, suggesting that the T cells
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Figure 2 MEDI-565/T-cell inhibits proliferation of CEAþ cancer cells. (A) AsPC-1 cells (5 10
5 per well) were cultured with or without T cells
(2.5 10
6 per well) for 7 days in 12-well plates in the presence of MEDI-565 or Cont BiTE (100ngml
 1). MEDI-565-induced T-cell cytotoxicity was
assessed by staining tumour cells with PE-labelled anti-CEA mAb and 7-AAD. Carcinoembryonic antigen-positive tumour cells were analysed for their 7-
AAD positivity. The assay was repeated four times and the average values of cytotoxicity for each condition are shown. *Po0.001 (Student’s t-test). (B)
MEDI-565 effect on tumour cell proliferation was assessed by counting cells with Trypan blue dye exclusion method. The assay was performed with
duplicated wells for each condition and the sum of viable cells (grey) and dead cells (black) are shown. (C, D) AsPC-1 cells (6 10
6 per flask) were
incubated with T cells (30 10
6 per flask) for 7 days in 150cm
2 flask. Floating cells were discarded and adherent cells were harvested with 0.05% trypsin/
EDTA. Cells were washed with PBS, resuspended and then fixed with cold 70% ethanol. Cells were stained with propidium iodide and samples were
acquired using a FACSCalibur flow cytometer and DNA content of tumour cells were analysed. The percentages of G0/G1, G2/M and S phases are shown
in each histogram (C). Harvested AsPC-1 cells (1 10
4 per well) were put into 96-well flat-bottom plates on day  1, and incubated overnight. On days 0, 1,
2, 4 and 7, the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide (MTT) assay was performed. In brief, 20mlo f1 0  MTT (5mgml
 1) solution
was added to each well, and incubated at 371C for 2h. Adherent cells were lysed with 150ml of dimethylsulphoxide (DMSO) at 371C for 5min, and OD
550nm was measured using an ELISA plate reader. Value of day 0 was used as a baseline data, and the ratios of OD550nm values of each time point were
plotted (D). *Po0.001 (Student’s t-test).
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sdo become activated and secrete cytokines when activated by
MEDI-565 bound to CEA on tumour cells; both Tc1 (Th1) and Tc2
(Th2) type cytokines were detected (Supplementary Figure 4).
Soluble CEA protein does not affect apoptosis induced by
T cells redirected by MEDI-565
As many colorectal cancer patients have large amounts of soluble
circulating CEA protein in their serum, the MEDI-565 antibody
might be competitively inhibited by binding soluble CEA before it
can bind membrane-bound CEA on tumour cells. We analysed
whether soluble CEA protein in clinically relevant concentrations
could affect MEDI-565-induced T-cell cytotoxicity in our assay
system. To the cell culture, CEA protein was added at concentra-
tions from 2.5 to 1000ngml
 1, and AsPC-1 cells and CRC010
colorectal cancer cell were used as target cells. Apoptosis at each
condition was compared with the apoptosis in MEDI-565/T-cell
culture without CEA protein (0ngml
 1) and shown as a
−5
0
5
10
15
20
C
y
t
o
t
o
x
i
c
i
t
y
 
(
%
)
C
y
t
o
t
o
x
i
c
i
t
y
 
(
%
)
C
y
t
o
t
o
x
i
c
i
t
y
 
(
%
)
25
30
35
MEDI-565 concentration (ng ml–1)
Normal donor T
−5
0
5
10
15
20
25
30
35
MEDI-565 concentration (ng ml–1)
Patient T
0
10
20
30
40
50
10000 1000 100 10 1 0.1 0.01 0
Concentration of BiTE (ng ml–1)
10000 1000 100 10 1 0.1 0.01 0
Concentration of BiTE (ng ml–1)
10000 1000 100 10 1 0.1 0.01 0
Concentration of BiTE (ng ml–1)
10000 1000 100 10 1 0.1 0.01 0
10000 1000 100 10 1 0.1 0.01 0 10000 1000 100 10 1 0.1 0.01 0
Concentration of BiTE (ng ml–1)
0
10
20
30
40
50
60
70
80
0
10
20
30
40
50
Ls174T
HCT116 SW480
0
10
20
30
40
50
AsPC-1
Figure 3 MEDI-565/T-cell-induced apoptotic cell death of a CEAþ tumour cell line. (A) MEDI-565 induced cytotoxic capacity of T cells derived from
colorectal cancer patients compared with normal healthy donor T cells. T cells were isolated from the PBMCs derived from normal healthy donors (left
panel) or colorectal cancer patients (right panel) using T-cell-negative isolation kit. Isolated T cells were co-cultured with AsPC-1 tumour cells in a 5:1
effector-to-target ratio in the presence of various concentrations of MEDI-565 (0.01B10000ngml
 1) in 96-well U-bottom plates as described in Materials
and Methods. Cells were incubated for 2 days, and the cytotoxicity was analysed using flow cytometry with 7-AAD staining. No significant difference
(P40.05 for Student’s t-test, see text) in MEDI-565-induced T-cell cytotoxicity was observed between T cells from cancer patients and T cells from normal
donors when compared at each concentration of MEDI-565. (B) Carcinoembryonic antigen (CEA) specificity of MEDI-565/T-cell mediated killing of tumour
cells. The CEAþ tumour cell lines (Ls174T and AsPC-1) and CEA-negative tumour cell lines (SW480 and HCT116) were incubated in a 96-well U-bottom
plate with T cells negatively isolated from the PBMCs of normal donors (triangle symbols) or cancer patients (square symbols). MEDI-565 or Cont BiTE was
put into the culture at the indicated concentrations. After 2 days of incubation, cells were harvested from the plates with 0.05% trypsin/EDTA and stained
with FITC-labelled anti-lineage marker and 7-AAD. The 7-AAD-positive cells in lineage marker negative cells are analysed and shown in each line graph.
(C, D) Effects of time and concentration of MEDI-565 on T-cell-induced apoptosis of CEAþ tumour cells. Both the AsPC-1 cells (1 10
5 cells per well)
and normal donor’s T cells (5 10
5 cells per well) were put into a 96-well U-bottom plate with indicated concentrations of MEDI-565 or Cont BiTE. After
4 days of incubation, cells were harvested with 0.05% trypsin/EDTA and labelled with biotin-labelled Annexin V, and then stained with FITC-anti-lineage
mixture, PE-anti-CEA, 7-AAD and streptavidin-APC. Lineage marker-negative and CEAþ tumour cells were analysed for their 7-AAD/Annexin V staining.
(C) The AsPC-1 cells were incubated with T cells in the presence of MEDI-565 or Cont BiTE (100ngml
 1) for 1, 2 or 4 days and stained as described in
(B). Percentages of annexin V-positive cells (including 7-AAD negative and 7-AAD positive) in CEAþ tumour cells are shown in each line graph.
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spercentage (Figure 5). In the tested range of soluble CEA protein,
there was no significant competitive inhibition of MEDI-565-
induced cytotoxicity. This result indicates that MEDI-565 may not
be competitively inhibited by elevated soluble CEA levels in the
serum of cancer patients.
CEAþ cancer cell lines remain sensitive to
T-cell-mediated killing despite repeated exposure to
T cells and MEDI-565
Many anticancer drugs will induce outgrowth of drug-resistant
cancer cells, and repeated treatments may become ineffective. To
test whether we could repeatedly treat tumour cells with MEDI-565
and T cells, we created an analogous in vitro model in which As
PC-1 cells were exposed to three cycles of killing by T cells in the
presence of MEDI-565 or Cont BiTE. Harvested cells were analysed
using flow cytometry for their susceptibility to MEDI-565/T-cell-
mediated apoptosis and levels of CEA expression each cycle. As
shown in Figure 6, AsPC-1 cells repeatedly exposed to MEDI-565/T
cell maintained their susceptibility to MEDI-565/T-cell-mediated
apoptosis at a similar level to non-treated AsPC-1 cells. It should
be noted that the CEA expression levels on the AsPC-1 cells
remained constant throughout the assay period (data not shown).
On the basis of this result, MEDI-565/T cells may not induce
escape mechanisms in cancer cells, and thus might be suitable for
long-term and repeated treatment.
DISCUSSION
The purpose of this study was to determine whether CEAþ
metastatic colorectal cancers from patients previously treated with
chemotherapy, but in whom the tumour was not eradicated, could
be recognised and killed by T cells. Using a novel technology to
redirect the specificity of T cells, we evaluated the efficacy of a
CEA/CD3- bispecific antibody of the BiTE class against human
colorectal cancer cell lines and metastatic colorectal cancer
explants. We confirmed that T-cell-mediated tumour cell death
occurred at very low concentrations of MEDI-565 (1ngml
 1) and
without the addition of costimulatory agents. Similar levels of
MEDI-565-redirected T-cell lysis were observed when T cells from
colorectal cancer patients or from normal healthy donors were
used. Importantly, MEDI-565/T-cell treatment could efficiently
induce cell death of colorectal cancer cells derived from different
patients. We found that anti-proliferative activity required MEDI-
565, T cells and target cells expressing CEA. T cells alone or T cells
with Control BiTE did not show these effects on CEA-expressing
cancer cells.
The results of our study are noteworthy for several reasons.
First, we showed that metastatic colorectal cancers, which had
survived previous conventional systemic therapy, could be killed
by a T-cell-mediated therapy. In addition, we analysed the
sensitivity of these tumour cells to oxaliplatin in vitro and found
that the IC50 (2.5 12.0 and 30.5mM) for inhibition of proliferation
was higher than the majority of 25 colorectal cancer cell lines we
had previously tested for sensitivity to oxaliplatin (such as LS180,
Colo205 and HCT8, which are considered sensitive with IC50
o0.3mM). Therefore, we believe that the colorectal cancer explants
are relatively oxaliplatin-insensitive tumour cells.
Second, the low concentrations of MEDI-565 required for
activity suggest a potent anti-tumour capacity (Figure 3). This
low concentration has been reported for other BiTE antibodies.
Bargou et al (2008) showed the safety of a BiTE antibody,
blinatumomab (a BiTE with dual specificity for CD19 and CD3), in
their clinical trial, and confirmed that responses to blinatumomab
as a single agent occurred in B-cell lymphoma patients at a serum
level of 0.6ngml
 1. This is about five orders of magnitude below
serum levels reported for the monoclonal antibody rituximab at
standard doses, which similarly elicits objective responses as a
single agent in this disease (Hainsworth et al, 2003; Ghielmini
et al, 2005). The enormous potency difference between the BiTE
blinatumomab and a conventional antibody could be explained by
a greater number of T cells attacking an individual tumour cell
(both due to more T cells that are able to recognise tumour and
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sproliferation of the engaged T cells) or more efficient lysis of
tumour cells by the engaged T cells (due to activation of T-cell-
mediated killing by engagement of only very few CD3 receptor
subunits). Interestingly, we observed the activation of both CD4
and CD8 T cells against tumour cells in the presence of MEDI-565
(Supplementary Figures 2 and 3). Consistent with our findings,
Kischel et al (2009) showed that both CD4 and CD8 T cell subset
can contribute to redirected target cell killing with EpCAM/CD3-
BiTE antibody. Thus, the high potency of BiTE molecule may
derive from a broader spectrum and a greater number of effector
T cells engaged to kill target cells. We also observed that the
number of T cells in the MEDI-565 co-cultures was greater than the
number placed into the cultures and was also greater than that in
the control BiTE cultures after 5 days, suggesting that there was
proliferation of the effector T cells. Finally, there was upregulation
of CD69 on these T cells, suggesting that they were activated.
Third, we showed that resistance to T-cell-mediated killing may
not occur. We created an in vitro model of repeated MEDI-565/T
cell exposure, by repeating three cycles of MEDI-565/T-cell attack
and rest with the CEA-expressing cell line AsPC-1. We observed
that these cells maintained their susceptibility to MEDI-565/T-cell
attack after prolonged treatment in vitro (Figure 6). Interestingly,
CEA expression of tumour cells was retained despite prolonged
treatment, suggesting that MEDI-565/T-cell treatment may not
easily induce escape mechanisms in cancer cells. Hypothetically,
re-treatment with MEDI-565 can be still effective for progressive
disease that was once treated with MEDI-565 successfully at its
earlier stages.
Fourth, we were concerned that the high circulating levels of
CEA could impair MEDI-565 function through competitive
inhibition of binding to surface CEA. As many colorectal cancer
patients have high levels of soluble CEA protein in their serum
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Figure 4 MEDI-565/T-cell-mediated apoptosis of CEAþ human metastatic colorectal cancer explants. (A) Colorectal cancer cells from liver metastatic
lesions, expanded NOD/SCID mice, excised and maintained in culture as described in the Materials and Methods, were incubated with MEDI-565 or MEC14
control BiTE (100ngml
 1). After 5 days of incubation, cells were harvested with 0.05% trypsin/EDTA, washed and stained with biotin-annexin V and
streptavidin-APC, FITC-anti-lineage marker, PE-anti-CEA and 7-AAD. Annexin V/7-AAD positivity was evaluated in lineage marker-negative, CEAþ tumour
cell populations using flow cytometry. The percentages of annexin V-positive cells are shown in each dot plot. (B) Co-incubation of T cells and colorectal
cancer cells (CRC007, CRC010 and CRC039) together with MEDI-565 or Cont BiTE was repeated twice, and the average percentages of apoptotic tumour
cells (Annexin Vþ) are shown in the bar graph. *Po0.005 (Student’s t-test). (C) Cells were counted with Trypan blue dye exclusion method. The numbers
of viable cells (grey) and dead cells (black) are shown in each bar graph. The error bars show s.d. of the total number of cells calculated from duplicate wells.
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s(Goldstein and Mitchell, 2005), an antibody may be less effective in
those patients. We studied whether soluble CEA inhibited the
function of MEDI-565. At clinically relevant concentrations of
soluble CEA (2.5–1000ngml
 1), 100ngml
 1 of MEDI-565 induced
similar levels of T-cell-mediated cell death compared with vehicle
control, suggesting no major inhibitory effect of soluble CEA
on MEDI-565 function (Figure 5). MEDI-565 does bind to soluble
CEA (data not shown) in competitive inhibition binding studies.
However, at physiological concentrations in the long term (424h)
in vitro assays in which equilibrium can be established, functional
activity of the MEDI-565 is not impaired. We speculate that the
assays showing tumour killing are more complex than receptor–
ligand binding interactions (e.g., competitive inhibition binding).
Nevertheless, the fact that a range of soluble CEA protein up to
1000ngml
 1 could not block MEDI-565-induced T-cell cytotoxi-
city suggests that endogenous circulating CEA may not impair the
clinical activity of MEDI-565. Furthermore, CEA-specificity studies
were conducted by Lutterbuese et al (2009) showing that the
MEDI-565 does indeed bind to CEA expressed on tumour.
Finally, because the molecular mechanism of T-cell cytotoxicity
induced by BiTE molecules is still not fully determined, we
performed additional studies and elucidated a role for granzyme B
and perforin-mediated cell killing (Supplementary Figures 2 and
3). Gruen et al (2004) reported that bispecific antibodies against
CD19 and CD3 (bscCD19xCD3) induced B-cell lysis in a perforin-
dependent, but death receptor-independent manner. Offner et al
(2006) analysed the immunological synapses of EpCAM-BiTE, and
showed the localisation of perforin and granzyme in lytic synapses
by immunofluorescence labelling. We also observed increased
percentages of granzyme B-positive CD8/CD4 T cells beginning on
day 2 and thereafter following the initiation of tumour/T-cell co-
incubation in the presence of MEDI-565 (Supplementary Figure 2).
Importantly, MEDI-565 significantly enhanced granzyme B secre-
tion by T cells from the early time point of co-incubation, and
gradually increased perforin levels in tumour/T-cell culture.
Induction of apoptotic cell death in the AsPC-1 cell line
corresponded well with this increase of perforin level, suggesting
that MEDI-565 induces perforin/granzyme B-dependent T-cell
cytotoxicity. Moreover, the addition of EGTA to the culture
significantly inhibited MEDI-565-mediated T-cell cytotoxicity
(data not shown), supporting the involvement of perforin, which
requires extracellular calcium for pore formation (Lowin et al,
1996; Voskoboinik et al, 2005). However, one criticism of this
proposed mechanism is that granzyme-mediated killing should be
rapid. One unusual finding in our study was that the cell death
associated with MEDI-565 occurred with a relatively slow onset
(Figure 3), and the peak of the tumour cell death was detected on
days 4 to 5 after the initiation of the tumour cell/T-cell co-
incubation with MEDI-565. This is unlike other reports of
bispecific antibodies of the BiTE class (Hoffmann et al, 2005;
Hammond et al, 2007). On the basis of Supplementary Figure 2, it
is possible that a critical concentration of perforin must be present
to allow sufficiently released granzyme B to accumulate in target
cells. We also found high-level secretion of several cytokines,
including IFN-g and TNF-a (Supplementary Figure 4), and further
analyses are needed to elucidate the role of these cytokines in
MEDI-565-redirected T-cell cytotoxicity.
In summary, human metastatic colorectal cancer, which had
survived previous systemic chemotherapy, was sensitive to T-cell-
mediated killing as shown using the novel CEA-specific BiTE
MEDI-565. We observed apoptosis induction as well as anti-
proliferative activity on tumour cells cultured with MEDI-565 and
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Figure 6 Repeated treatment with MEDI-565 and T cells does not
abolish tumour cell susceptibility to MEDI-565/T-ell-mediated apoptosis.
AsPC-1 tumour cells (6 10
6) were cultured with T cells (3 10
7)i n
150cm
2 T flasks with MEDI-565 or Cont BiTE (100ngml
 1). Additional
BiTE molecules were added every 3 days, and after 10-day incubation,
floating cells were washed out and cells were allowed to expand for 7 days
(one cycle). Three cycles of attack/rest were repeated for each condition
over 50 days. Adherent AsPC-1 cells were harvested and used as target
cells for cytotoxicity assay. After 5 days of incubation with T cells, tumour
cells were stained as described in the Figure 4 legend. Annexin V-positive
cells in lineage marker-negative, CEAþ tumour cells were evaluated. The
cytotoxicity value of the incubation with AsPC-1 target cells from long-term
culture without BiTE molecule was set as 100%, and each cytotoxicity value
is shown as a percentage relative to this condition. The assay was repeated
twice with similar results.
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Figure 5 Soluble CEA protein does not affect MEDI-565/T-cell-
mediated apoptosis of CEAþ cell line and colorectal cancer cells. AsPC-
1 cells or CRC010 colorectal cancer cells (5 10
5 cells per well) were
incubated with T cells (2.5 10
6 cells per well) in a 12-well plate in the
presence of MEDI-565 (100ngml
 1; 1.8nM) with the indicated concentra-
tion of soluble CEA antigen in the medium (2.5B1000ngml
 1; 0.01 to
5n M). After 5 days of incubation, tumour cells were harvested and stained
as described in the Figure 4 legend. Annexin V-positive cells in lineage
marker-negative, CEAþ tumour cells were evaluated. The cytotoxicity
value of the culture with MEDI-565 without soluble CEA protein was set as
100%, and each cytotoxicity value is shown as a percentage relative to this
MEDI-565-positive, CEA protein-negative culture. The assay was repeated
twice for both AsPC-1 cells and CRC010 cancer cells (filled symbols
indicate AsPC-1 cells and open symbols indicate CRC010 tumour cells;
each symbol represents an individual T-cell donor). The bars show the
average cytotoxicities of each condition.
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sT cells, and showed that perforin/granzyme B had a key role in
cytotoxicity. As CEA is expressed by many different kinds of
cancers, MEDI-565 may be applicable to a wide range of
adenocarcinoma as a novel treatment with the potential for high
efficacy and less toxicity than conventional therapies. The next
studies will be in vivo models to confirm activity against implanted
colorectal cancers and if the results continue to show anti-tumour
activity, these data would support the initiation of clinical trials
with this therapy.
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